Vinorelbine Tartrate

Appearance:Solid powder
Purity: > 98%

Cat No:	A000151
Cas No:	125317-39-7
Product-Name:	Vinorelbine Tartrate
MDL No:	MFCD03613607
InChI:	InChI=1S/C45H54N4O8.2C4H6O6/c1-8-27-19-28-22-44(40(51)55-6,36-30(25-48(23-27)24-28)29-13-10-11-14-33(29)46-36)32-20-31-34(21-35(32)54-5)47(4)38-43(31)16-18-49-17-12-15-42(9-2,37(43)49)39(57-26(3)50)45(38,53)41(52)56-7;2*5-1(3(7)8)2(6)4(9)10/h10-15,19-21,2
InChIKey:	CILBMBUYJCWATM-NPJYPKOYSA-N
SMILES:	CCC1=CC2CC(C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC.C(C(C(=O)O)O)(C(=O)O)O.C(C(C(=O)O)O)(C(=O)O)O

Vinorelbine is a semisynthetic vinca alkaloid derived from the leaves of the periwinkle plant (Vinca rosea) with antineoplastic activity. Vinorelbine binds to tubulin, thereby inhibiting tubulin polymerization into microtubules and spindle formation and resulting in apoptosis of susceptible cancer cells. Inhibition of mitotic microtubules correlates with antitumor activity, whereas inhibition of axonal microtubules seems to correlate with vinorelbine/'s neurotoxicity. Compared to related vinca alkaloids, vinorelbine is more selective against mitotic than axonal microtubules in vitro, which may account for its decreased neurotoxicity. This agent is also a radiation-sensitizing agent.

1: Jimeno A, Hitt R, Quintela-Fandino M, Cortés-Funes H. Phase II trial of vinorelbine tartrate in patients with treatment-naive metastatic melanoma. Anticancer Drugs. 2005 Jan;16(1):53-7. PubMed PMID: 15613904.
2: Whitehead RP, Moon J, McCachren SS, Hersh EM, Samlowski WE, Beck JT, Tchekmedyian NS, Sondak VK; Southwest Oncology Group. A Phase II trial of vinorelbine tartrate in patients with disseminated malignant melanoma and one prior systemic therapy: a Southwest Oncology Group study. Cancer. 2004 Apr 15;100(8):1699-704. PubMed PMID: 15073859.
3: Uoshima N, Yoshioka K, Tegoshi H, Wada S, Fujiwara Y, Satake N, Kasamatsu Y, Yokoho S. Acute respiratory failure caused by vinorelbine tartrate in a patient with non-small cell lung cancer. Intern Med. 2001 Aug;40(8):779-82. PubMed PMID: 11518124.
4: Bosque E. Possible drug interaction between itraconazole and vinorelbine tartrate leading to death after one dose of chemotherapy. Ann Intern Med. 2001 Mar 6;134(5):427. PubMed PMID: 11242511.
5: Kanazawa J, Morimoto M, Ohmori K. [Properties of antitumor activity of vinorelbine tartrate, a new vinca alkaloid antitumor agent]. Nihon Yakurigaku Zasshi. 2000 Oct;116(4):215-23. Review. Japanese. PubMed PMID: 11084918.
6: Giannios J, Ginopoulos P. Induction of PCD in tamoxifen-resistant oestrogen receptor positive (ER+) advanced breast cancer after combined therapy with ER antisense oligonucleotides and vinorelbine-tartrate encapsulated in DRV liposomes. Eur J Cancer. 2000 Sep;36 Suppl 4:103. PubMed PMID: 11056347.
7: Feun LG, Savaraj N, Hurley J, Marini A, Lai S. A clinical trial of intravenous vinorelbine tartrate plus tamoxifen in the treatment of patients with advanced malignant melanoma. Cancer. 2000 Feb 1;88(3):584-8. PubMed PMID: 10649251.
8: Balthasar JP. Concentration-dependent incompatibility of vinorelbine tartrate and heparin sodium. Am J Health Syst Pharm. 1999 Sep 15;56(18):1891. PubMed PMID: 10511236.
9: Cattan CE, Oberg KC. Vinorelbine tartrate-induced pulmonary edema confirmed on rechallenge. Pharmacotherapy. 1999 Aug;19(8):992-4. PubMed PMID: 10453972.
10: Kouroukis C, Hings I. Respiratory failure following vinorelbine tartrate infusion in a patient with non-small cell lung cancer. Chest. 1997 Sep;112(3):846-8. PubMed PMID: 9315826.